stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) Return on invested capital
ACADIA Pharmaceuticals Inc.'s return on invested capital over the twelve months to 30 September 2026 was 18.6%, up 2.5 percentage points from fiscal 2025 (16.1%). Over the past ten years it has ranged from −9,032.3% (fiscal 2019) to 16.1% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 16.1% | 16.07 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 527.66 |
| FY2021 | −527.7% | (527.66) |
| FY2020 | 0.00% | 9,032.28 |
| FY2019 | −9,032.3% | (6,250.26) |
| FY2018 | −2,782.0% | (2,782.02) |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. | 18.6% |
| RLAY Relay Therapeutics, Inc. compare | 0.00% |
| IRON Disc Medicine, Inc. compare | 0.00% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| IOVA Iovance Biotherapeutics, Inc. compare | −17.7% |
| XENE Xenon Pharmaceuticals Inc. compare | −88.5% |
| TNGX Tango Therapeutics, Inc. compare | −808.4% |
| DYN Dyne Therapeutics, Inc. compare | −1,956.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on ACAD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement